Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies. J of Skin 2022, 6 (2), s28. https://doi.org/10.25251/skin.6.supp.28.